## UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FIRST QUARTER ENDED 31 MARCH 2022

		Individua	l quarter	Cumulative quarter		
	Note	Current year quarter 31/03/2022 RM'000	Preceding year quarter 31/03/2021 RM'000	Current year- to-date 31/03/2022 RM'000	Preceding year-to-date 31/03/2021 RM'000	
Revenue		46,221	37,735	46,221	37,735	
Cost of sales		(32,301)	(25,604)	(32,301)	(25,604)	
Gross profit		13,920	12,131	13,920	12,131	
Other operating income		166	309	166	309	
Distribution costs		(2,521)	(2,721)	(2,521)	(2,721)	
Administration expenses		(6,310)	(5,203)	(6,310)	(5,203)	
Finance costs		(408)	(375)	(408)	(375)	
Profit before tax		4,847	4,141	4,847	4,141	
Tax expense	B5	(1,317)	(1,024)	(1,317)	(1,024)	
Profit for the financial period		3,530	3,117	3,530	3,117	
Other comprehensive income, net of tax		-	-	-	-	
Total comprehensive income		3,530	3,117	3,530	3,117	
Profit attributable to:						
Owners of the parent		3,456	3,015	3,456	3,015	
Non-controlling interests		74	102	74	102	
C		3,530	3,117	3,530	3,117	
Total comprehensive income attributable to:						
Owners of the parent		3,456	3,015	3,456	3,015	
Non-controlling interests		74	102	74	102	
		3,530	3,117	3,530	3,117	
Earnings per ordinary share attributable to owners of the parent:						
- Basic (sen)	B15	1.68	1.50	1.68	1.50	
- Diluted (sen)	B15	1.21	1.07	1.21	1.07	

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

# UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2022

	Note	As at 31/03/2022 RM'000	Audited As at 31/12/2021 RM'000
Non-current asset			
Property, plant and equipment		78,059	78,523
Right-of-use assets		11,002	11,141
Investment property		5,557	5,567
Biological assets		3,455	3,367
Goodwill		3,941	3,941
Other investment	B9	74	24
	-	102,088	102,563
Current assets			
Inventories		36,831	33,246
Trade and other receivables		34,560	38,578
Current tax assets		668	799
Cash and bank balances and short term funds		34,103	20,620
	<del>-</del> _	106,162	93,243
Total assets	_	208,250	195,806
	_	_	
Equity		115.056	102 (10
Share capital	D17	117,076	103,618
Reorganisation debit balance	B17	(59,489)	(59,489)
Retained earnings	_	90,692	87,236
Total attributable to owners of the parent		148,279	131,365
Non-controlling interests	_	7,862	7,788
Total equity	<del>-</del>	156,141	139,153
Non-current liabilities			
Borrowings	B10	24,626	25,698
Lease liabilities		93	177
Deferred tax liabilities		1,918	1,918
Deferred income		397	400
	_	27,034	28,193
Current Liabilities			
		16,180	19,835
Trade and other payables	B10	7,128	7,087
Borrowings	DIO	315	315
Lease liabilities		14	14
Deferred income			
Current tax liabilities	_	1,438	1,209
	_	25,075	28,460
Total liabilities	-	52,109	56,653
Total equity and liabilities	_	208,250	195,806

# UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2022 (CONTINUED)

	Note	As at 31/03/2022	Audited As at 31/12/2021
Net assets per share attributable to owners of the parent (RM)	B16	0.67	0.65

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

## UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED 31 MARCH 2022

	<>					
	< Non-dist	<> Non-distributable> Distributable				
	Share capital RM'000	Reorganisation debit balance RM'000	Retained earnings RM'000	Total attributable to owners of the parent RM'000	Non- controlling interest RM'000	Total equity RM'000
Balance as at 1 January 2022	103,618	(59,489)	87,236	131,365	7,788	139,153
Profit for the financial period Other comprehensive income, net of tax Total comprehensive income		-	3,456	3,456	74 - 74	3,530
Total comprehensive income		-	3,456	3,456	/4	3,530
Transactions with owners: Issuance of ordinary shares Total transactions with owners	13,458 13,458	<u>-</u>	<u>-</u>	13,458 13,458	<del>-</del>	13,458 13,458
Balance as at 31 March 2022	117,076	(59,489)	90,692	148,279	7,862	156,141
Balance as at 1 January 2021	103,618	(59,489)	79,985	124,114	6,537	130,651
Profit for the financial period Other comprehensive income, net of tax	-	- -	3,015	3,015	102	3,117
Total comprehensive income	=	=	3,015	3,015	102	3,117
Transactions with owners: Dividends paid Total transactions with owners		<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Balance as at 31 March 2021	103,618	(59,489)	83,000	127,129	6,639	133,768

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

## UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FIRST QUARTER ENDED 31 MARCH 2022

Cash flows from operating activities           Profit before tax         4,847         4,141           Adjustments for:         906         739           Depreciation         906         739           Inventories written off         47         13           Inventories written down         119         1           Impairment losses on trade receivables         90         120           Interest expense         408         375           Loss on disposal of biological assets         13         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (966)         (881)           Net cash from investing activities         1,849         700		Current year- to-date 31/03/2022 RM'000	Preceding year-to-date 31/03/2021 RM'000
Adjustments for:   Depreciation   906   739   Inventories written off   47   13   11   11   11   11   11   11   1	Cash flows from operating activities		
Depreciation         906         739           Inventories written off         47         13           Inventories written down         119         1           Impairment losses on trade receivables         90         120           Interest expense         408         375           Loss on disposal of biological assets         13         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         (3751)         (525)           Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)	Profit before tax	4,847	4,141
Inventories written off         47         13           Inventories written down         119         1           Impairment losses on trade receivables         90         120           Interest expense         408         375           Loss on disposal of biological assets         13         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         (3,751)         (525)           Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         2         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets <td>Adjustments for:</td> <td></td> <td></td>	Adjustments for:		
Inventories written down         119         1           Impairment losses on trade receivables         90         120           Interest expense         408         375           Loss on disposal of biological assets         113         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Urrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal o	Depreciation	906	739
Impairment losses on trade receivables         90         120           Interest expense         408         375           Loss on disposal of biological assets         13         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         (3,751)         (525)           Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets <t< td=""><td>Inventories written off</td><td>47</td><td>13</td></t<>	Inventories written off	47	13
Interest expense         408         375           Loss on disposal of biological assets         13         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:	Inventories written down	119	1
Loss on disposal of biological assets         13         58           Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities <tr< td=""><td>Impairment losses on trade receivables</td><td>90</td><td>120</td></tr<>	Impairment losses on trade receivables	90	120
Fair value changes on biological assets         (114)         (137)           Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:         Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069) <t< td=""><td>Interest expense</td><td>408</td><td>375</td></t<>	Interest expense	408	375
Interest income         (30)         (42)           Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:	Loss on disposal of biological assets	13	58
Unrealised loss/(gain) on foreign currency exchange         217         (187)           Operating profit before working capital changes         6,503         5,081           Changes in working capital:	Fair value changes on biological assets	(114)	(137)
Operating profit before working capital changes         6,503         5,081           Changes in working capital:         (3,751)         (525)           Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         - </td <td>Interest income</td> <td>(30)</td> <td>(42)</td>	Interest income	(30)	(42)
Changes in working capital:         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         1	Unrealised loss/(gain) on foreign currency exchange	217	(187)
Inventories         (3,751)         (525)           Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483	Operating profit before working capital changes	6,503	5,081
Trade and other receivables         3,928         (652)           Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of fin	Changes in working capital:		
Trade and other payables         (3,875)         (2,523)           Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Inventories	(3,751)	(525)
Cash generated from operations         2,805         1,381           Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Trade and other receivables	3,928	(652)
Tax paid         (956)         (681)           Net cash from operating activities         1,849         700           Cash flows from investing activities         \$\$\$\$ Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Trade and other payables	(3,875)	(2,523)
Net cash from operating activities         1,849         700           Cash flows from investing activities         Varieties         Varieties           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities         Value of the cash in the cash used in investing activities         (1,032)         (1,069)           Interest paid         (404)         (367)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Cash generated from operations	2,805	1,381
Cash flows from investing activities           Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Tax paid	(956)	(681)
Purchase of property, plant and equipment         (293)         (1,527)           Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Net cash from operating activities	1,849	700
Interest received         30         42           Acquisition of quoted shares         (50)         -           Proceeds from disposal of biological assets         13         30           Net cash used in investing activities         (300)         (1,455)           Cash flows from financing activities         **         **           Net repayment of borrowings         (1,032)         (1,069)           Interest paid         (404)         (367)           Payment of lease liabilities         (88)         (172)           Proceeds from issuance of shares         13,458         -           Net cash from/(used in) financing activities         11,934         (1,608)           Net increase/(decrease) in cash and cash equivalents         13,483         (2,363)           Cash and cash equivalents at beginning of financial period         20,620         24,476	Cash flows from investing activities		
Acquisition of quoted shares       (50)       -         Proceeds from disposal of biological assets       13       30         Net cash used in investing activities       (300)       (1,455)         Cash flows from financing activities         Net repayment of borrowings       (1,032)       (1,069)         Interest paid       (404)       (367)         Payment of lease liabilities       (88)       (172)         Proceeds from issuance of shares       13,458       -         Net cash from/(used in) financing activities       11,934       (1,608)         Net increase/(decrease) in cash and cash equivalents       13,483       (2,363)         Cash and cash equivalents at beginning of financial period       20,620       24,476	Purchase of property, plant and equipment	(293)	(1,527)
Proceeds from disposal of biological assets Net cash used in investing activities  Cash flows from financing activities  Net repayment of borrowings Interest paid Payment of lease liabilities Proceeds from issuance of shares Net cash from/(used in) financing activities  Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents at beginning of financial period  13 30 (1,050) (1,455)  (1,069)	Interest received	30	42
Net cash used in investing activities(300)(1,455)Cash flows from financing activitiesValue of the payment of borrowings(1,032)(1,069)Interest paid(404)(367)Payment of lease liabilities(88)(172)Proceeds from issuance of shares13,458-Net cash from/(used in) financing activities11,934(1,608)Net increase/(decrease) in cash and cash equivalents13,483(2,363)Cash and cash equivalents at beginning of financial period20,62024,476	Acquisition of quoted shares	(50)	-
Cash flows from financing activities  Net repayment of borrowings (1,032) (1,069)  Interest paid (404) (367)  Payment of lease liabilities (88) (172)  Proceeds from issuance of shares 13,458 -  Net cash from/(used in) financing activities 11,934 (1,608)  Net increase/(decrease) in cash and cash equivalents 13,483 (2,363)  Cash and cash equivalents at beginning of financial period 20,620 24,476	Proceeds from disposal of biological assets	13	30
Net repayment of borrowings(1,032)(1,069)Interest paid(404)(367)Payment of lease liabilities(88)(172)Proceeds from issuance of shares13,458-Net cash from/(used in) financing activities11,934(1,608)Net increase/(decrease) in cash and cash equivalents13,483(2,363)Cash and cash equivalents at beginning of financial period20,62024,476	Net cash used in investing activities	(300)	(1,455)
Net repayment of borrowings(1,032)(1,069)Interest paid(404)(367)Payment of lease liabilities(88)(172)Proceeds from issuance of shares13,458-Net cash from/(used in) financing activities11,934(1,608)Net increase/(decrease) in cash and cash equivalents13,483(2,363)Cash and cash equivalents at beginning of financial period20,62024,476	Cash flows from financing activities		
Interest paid (404) (367) Payment of lease liabilities (88) (172) Proceeds from issuance of shares 13,458 - Net cash from/(used in) financing activities 11,934 (1,608)  Net increase/(decrease) in cash and cash equivalents 13,483 (2,363) Cash and cash equivalents at beginning of financial period 20,620 24,476		(1,032)	(1,069)
Payment of lease liabilities (88) (172) Proceeds from issuance of shares 13,458 - Net cash from/(used in) financing activities 11,934 (1,608)  Net increase/(decrease) in cash and cash equivalents 13,483 (2,363) Cash and cash equivalents at beginning of financial period 20,620 24,476	• •		* ' '
Proceeds from issuance of shares 13,458 - Net cash from/(used in) financing activities 11,934 (1,608)  Net increase/(decrease) in cash and cash equivalents 13,483 (2,363) Cash and cash equivalents at beginning of financial period 20,620 24,476		, ,	
Net cash from/(used in) financing activities11,934(1,608)Net increase/(decrease) in cash and cash equivalents13,483(2,363)Cash and cash equivalents at beginning of financial period20,62024,476	· · · ·		_
Cash and cash equivalents at beginning of financial period 20,620 24,476	Net cash from/(used in) financing activities		(1,608)
Cash and cash equivalents at beginning of financial period 20,620 24,476	Net increase/(decrease) in cash and cash equivalents	13,483	(2,363)
	•		

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

## A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

#### A1. Basis of preparation

The unaudited interim financial statements have been prepared in accordance with the requirements of MFRS 134 *Interim Financial Reporting* and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021 and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2021.

#### **A2.** Significant accounting policies

The significant accounting policies and methods of computation adopted for the interim financial statements are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2021, except for the adoption of the following amendments to MFRSs during the financial year:

- Annual Improvements to MFRS Standards 2018 2020
- Amendments to MFRS 3 Reference to the Conceptual Framework
- Amendments to MFRS 116 Property, Plant and Equipment Proceeds before Intended Use
- Amendments to MFRS 137 Onerous Contracts Cost of Fulfilling a Contract

The adoption of the above amendments had no significant impact to the financial statements of the Group.

#### A3. Auditors' report

There was no qualification to the audited financial statements of the Company and its subsidiaries for the financial year ended 31 December 2021.

#### A4. Seasonal or cyclical factors

The business operations of the Group were not materially affected by any seasonal and cyclical factors during the current quarter and financial year-to-date under review.

#### A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group for the current quarter and financial year-to-date under review.

#### A6. Changes in estimates

There were no changes in estimates that have a material effect in the current quarter and financial year-to-date under review.

#### A7. Debt and equity securities

On 8 February 2022, Public Investment Bank Berhad ("PIVB") had on behalf of the Board of Directors of the Company, announced that the Company proposes to undertake a proposed private placement of up to 28,120,300 new ordinary shares in the Company ("Placement

Share(s)"), representing up to 10% of the enlarged number of issued shares in the Company ("Proposed Private Placement").

The Company further announced on 14 February 2022 that Bursa Malaysia Securities Berhad ("Bursa Securities") had, via its letter dated 14 February 2022, approved the listing and quotation of up to 28,120,300 Placement Shares to be issued pursuant to the Proposed Private Placement on the Main Market of Bursa Securities, subject to the conditions set out in Bursa Securities' letter.

On 11 March 2022, the Company announced that the private placement of up to 28,120,300 new shares in the Company representing up to 10% of the enlarged number of issued shares of the Company ("Private Placement") has been fixed at RM0.67 per Placement Share and will comprise up to 20,086,000 Placement Shares.

On 14 March 2022, the Company announced that the Private Placement has been completed following the listing of and quotation for 20,086,000 Placement Shares on the Main Market of Bursa Securities with effect from 9.00 a.m. on 14 March 2022.

Pursuant to Private Placement, the issued shares of the Company increased from 200,860,000 ordinary shares to 220,946,000 ordinary shares.

Save for the above, there were no other issuance, cancellation, repurchase, resale or repayment of debt and equity securities for the current quarter and financial year-to-date under review.

#### A8. Dividend

On 24 December 2021, the Board of Directors declared an interim single tier dividend of 1.0 sen per ordinary share totalling RM2.01 million in respect of the financial year ended 31 December 2021. The dividend had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2021 and was paid on 25 January 2022 to shareholders registered at the close of business on 13 January 2022.

#### A9. Segmental information

The Group's operating segments are animal health products and equipment, food ingredients and others. These operating segments are required to be organised and managed separately according to the nature of products and services as well as specific expertise which require different business and marketing strategies. The segmental results are as follows:

	Individua	ıl quarter	Cumulativ	e quarter
	Current year quarter 31/03/2022 RM'000	Preceding year quarter 31/03/2021 RM'000	Current year- to-date 31/03/2022 RM'000	Preceding year-to-date 31/03/2021 RM'000
Revenue				
Animal health products and equipment	34,212	29,446	34,212	29,446
Food ingredients	8,692	6,046	8,692	6,046
Others	3,317	2,243	3,317	2,243
	46,221	37,735	46,221	37,735

	Individua	l quarter	Cumulativ	e quarter
	Current year quarter 31/03/2022 RM'000	Preceding year quarter 31/03/2021 RM'000	Current year- to-date 31/03/2022 RM'000	Preceding year-to-date 31/03/2021 RM'000
Profit before tax				
Animal health products and equipment	3,932	3,393	3,932	3,393
Food ingredients	1,051	436	1,051	436
Others	(136)	312	(136)	312
	4,847	4,141	4,847	4,141

#### A10. Property, plant and equipment

#### (i) Acquisitions and disposals

There were no material acquisitions and disposals during the current quarter and financial year-to-date under review.

#### (ii) Impairment losses

There were no material impairment losses during the current quarter and financial year-to-date under review.

#### (iii) Valuation

The Group has not carried out any valuation on its property, plant and equipment during the current quarter and financial year-to-date under review.

### A11. Material events subsequent to the end of the quarter

There were no material events subsequent to the end of the current quarter that have not been reflected in this interim financial report.

#### A12. Changes in the composition of the Group

There were no changes in the composition of the Group during the current quarter and financial year-to-date under review.

#### A13. Contingent liabilities and contingent assets

There were no contingent liabilities or contingent assets as at the date of this report.

#### A14. Capital commitments

The capital commitments of the Group as at the end of the quarter under review were as follows:

	RM'000
Approved and contracted for:	
- Construction of GMP-compliant plant in Nilai, Negeri Sembilan	2,495
- Machineries and equipment	1,110
	3,605

## A15. Significant related party transactions

The related party transactions during the current quarter and financial year-to-date under review are as follows:

	Individua Current year quarter 31/03/2022 RM'000	al quarter Preceding year quarter 31/03/2021 RM'000	Cumulati Current year-to-date 31/03/2022 RM'000	Preceding year-to-date 31/03/2021 RM'000
Nor Livestock Farm Sdn Bhd ("NLF") purchases milk replacer from Nor Lazuli Nutrition ("NLN")	-	8	-	8
NLN purchases hay from NLF	-	14	-	14
One Lazuli Sdn Bhd ("OLSB") purchases feed from NLN	-	4	-	4
OLSB provides transportation services to NLN	-	4	-	4
NLF purchases anti- inflammatory medication, mastitis medication, antibiotics, anti-parasitics and dairy milk machine parts from OLSB	-	14	-	14
NLN rents an office space from OLSB	-	3	-	3
NLF rents an office space from OLSB	-	1	-	1
NLF rents a farm land from Raja Mariam Binti Raja Rustam Shahrome, Dr Mai Lam @ Rosli Mai Lam and Melissa Aini Mai	8	8	8	8
NLN rents a factory building from Raja Mariam Binti Raja Rustam Shahrome, Dr Mai Lam @ Rosli Mai Lam and Melissa Aini Mai	8	8	8	8
OLSB rents an office space from Raja Mariam Binti Raja Rustam Shahrome	45	45	45	45

## B. ADDITIONAL INFORMATION REQUIRED BY THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

#### **B1.** Review of performance

The Group recorded revenue of approximately RM46.22 million for the current quarter, an increase of approximately RM8.48 million compared to the revenue of approximately RM37.74 million in the preceding year's corresponding quarter. Revenue from animal health products and equipment increased by approximately RM4.76 million from approximately RM29.45 million in the preceding year's corresponding quarter to approximately RM34.21 million in the current quarter. Revenue from food ingredients increased by approximately RM2.64 million from approximately RM6.05 million in the preceding year's corresponding quarter to approximately RM8.69 million in the current quarter. Revenue from the dairy business which is categorised under others segment, increased by approximately RM0.37 million from approximately RM1.56 million in the preceding year's corresponding quarter to approximately RM1.93 million in the current quarter.

In line with the increase in revenue, the Group's profit before tax for the current quarter of approximately RM4.85 million was approximately RM0.71 million higher compared to the profit before tax of approximately RM4.14 million reported for the preceding year's corresponding quarter.

### B2. Material changes in the quarterly results compared to the immediate preceding quarter

The Group's revenue of approximately RM46.22 million for the current quarter was approximately RM2.80 million lower compared to the revenue of approximately RM49.02 million reported for the preceding quarter. The decrease in revenue is mainly due to lower revenue from animal health products and equipment which decreased by approximately RM4.20 million from approximately RM38.41 million in the preceding quarter to approximately RM34.21 million in the current quarter.

In line with the decrease in revenue, the Group's profit before tax for the current quarter of approximately RM4.85 million was approximately RM0.74 million lower compared to the profit before tax of approximately RM5.59 million reported for the preceding quarter.

#### **B3.** Prospects

The continued expansion of our operations through our future plans would provide a platform to grow and sustain our business. The Group will continue to focus on strengthening its production capabilities, product competitiveness and market position, while constantly seeking ways to mitigate the risks associated with its business. The Group will also continue to improve its internal controls and processes based on prudent management practices. In addition to improving on current operations, the Group is vigilant in identifying new business opportunities that has the potential for continuous growth and expansion.

In line with the projected growth of the Malaysian economy, the livestock industry is also anticipated to grow due to the corresponding growing Malaysian population resulting in the demand for meat as a source of protein to soar. The estimated increase in livestock in Malaysia is expected to result in correlating increase in demand for animal pharmaceutical and veterinary products, including animal feed to meet the rising needs. This is expected to augur well for the Group to ride on the growth trajectory in line with the government's endeavour to develop a sustainable livestock industry in the country for national food security. We are also anticipating growth in our dairy production business segment due to the projected uptrend in the local market. The production of milk in Malaysia was expected to increase in line with the government's aim to increase the country's fresh milk self-sufficiency level to 100% within five years and this will create abundant opportunities for the Group to capitalise on.

Based on the above, the Board is cautiously optimistic on the prospects and outlook of the Group as it enters into a post Covid-19 landscape. However, the Group remains cognisant of the emergence of new Covid-19 variants and will exercise caution in managing the Group's business operations and aims to improve its efficiency and resilience in order to mitigate risks of a re-imposition of lockdown measures.

#### **B4.** Profit forecast

The Group has not issued any profit forecast in any form of public documentation and announcement.

#### **B5.** Tax expense

	Individu	al quarter	Cumulati	Cumulative quarter	
	Current year quarter 31/03/2022 RM'000	Preceding year quarter 31/03/2021 RM'000	Current year-to-date 31/03/2022 RM'000	Preceding year-to-date 31/03/2021 RM'000	
Current tax					
Current year	1,317	1,024	1,317	1,024	

The effective tax rates of the Group for the current quarter and financial year-to-date of 27.17% was higher than the statutory tax rate of 24.00% as certain subsidiaries were in loss making positions and that certain expenses were not allowable for tax purposes.

## **B6.** Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Individua	l quarter	Cumulativ	<b>Cumulative quarter</b>		
	Current year Precedin year quarter 31/03/2022 31/03/202		Current year-to-date 31/03/2022	Preceding year-to-date 31/03/2021		
	RM'000	RM'000	RM'000	RM'000		
Profit before tax is arrived at after charging / (crediting):						
Depreciation	906	739	906	739		
Inventories written off	47	13	47	13		
Inventories written down	119	1	119	1		
Impairment losses on trade						
receivables	90	120	90	120		
Interest expense	408	375	408	375		
Loss on disposal of biological assets	13	58	13	58		
Fair value changes on						
biological assets	(114)	(137)	(114)	(137)		
Interest income	(30)	(42)	(30)	(42)		
Loss on foreign currency						
exchange	115	4	115	4		

Save for the above, the other items as required under Appendix 9B Part A (16) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad are not applicable.

## **B7.** Status of corporate proposals

There is no corporate proposal announced but not completed as at the date of this report.

### **B8.** Utilisation of proceeds

The status of utilisation of proceeds of approximately RM13.46 million from the Company's Private Placement of 20,086,000 new ordinary shares at RM0.67 each as at 31 March 2022 is as follows:

Details of the utilisation of proceeds	Proposed utilisation RM'000	Actual utilisation RM'000	Balance unutilised RM'000	Estimated timeframe for utilisation
Establishment of a milk processing plant	7,500	-	7,500	Within 36 months
Marketing expenses	2,500	-	2,500	Within 36 months
Working capital	3,008	-	3,008	Within 12 months
Estimated expenses for the Private Placement	450	-	450	Within 1 month
Total	13,458	-	13,458	

The utilisation of the proceeds as disclosed above should be read in conjunction with the Company's announcement dated 8 February 2022 and 11 February 2022.

#### **B9.** Other investment

	As at 31/03/2022 RM'000	As at 31/12/2021 RM'000
Financial asset at fair value through profit or loss		
Quoted shares in Malaysia	50	50
Acquisition of quoted shares	50	-
Less: Impairment loss	(26)	(26)
	74	24

#### **B10.** Borrowings

	As at 31/03/2022 RM'000	As at 31/12/2021 RM'000
Non-current liabilities (secured)		
Term loans	24,626	25,698
Current liabilities (secured)		
Bank overdrafts	2,549	2,508
Term loans	4,579	4,579
	7,128	7,087
Total borrowings	31,754	32,785

All borrowings are denominated in Ringgit Malaysia.

#### **B11.** Material litigation

There was no litigation which has a material effect on the financial position of the Group and the Board was not aware of any proceedings pending or of any fact likely to give rise to any proceedings as at the date of this report.

#### B12. Dividend

The Directors proposed a final single tier dividend of 1.0 sen per ordinary share in respect of the financial year ended 31 December 2021, subject to the approval of members at the forthcoming Annual General Meeting. This dividend, if approved by the shareholders, will be accounted for in equity as an appropriation of retained earnings in the financial year ending 31 December 2022.

#### **B13.** Derivative financial instruments

The Group does not have any derivative financial instruments as at the end of the current quarter.

#### B14. Gains/losses arising from fair value changes of financial liabilities

There were no material gains or losses arising from fair value changes of financial liabilities during the current quarter and financial year-to-date under review.

#### **B15.** Earnings per share

	Individual quarter		Cumulativ	Cumulative quarter	
	Current year quarter 31/03/2022	Preceding year quarter 31/03/2021	Current year-to-date 31/03/2022	Preceding year-to-date 31/03/2021	
Profit attributable to owners of the parent (RM'000)	3,456	3,015	3,456	3,015	
Weighted average number of ordinary shares in issue ('000)	205,770	200,860	205,770	200,860	
Shares under warrant deemed to have been issued for no consideration ('000)	80,344	80,344	80,344	80,344	
Weighted average number of ordinary shares for computing diluted earnings per share ('000)	286,114	281,204	286,114	281,204	
Earnings per share					
- Basic (sen)	1.68	1.50	1.68	1.50	
- Diluted (sen)	1.21	1.07	1.21	1.07	

### **B16.** Net assets per share

Net assets per share attributable to owners of the parent is arrived at by dividing the total equity attributable to owners of the parent at the end of the financial period by the number of ordinary shares in issue at the end of the financial period.

	As at 31/03/2022	As at 31/12/2021
Total equity attributable to owners of the parent (RM'000)	148,279	131,365
Number of ordinary shares in issue ('000)	220,946	200,860
Net assets per share attributable to owners of the parent (RM)	0.67	0.65

### **B17.** Reorganisation debit balance

The reorganisation debit balance arose from the acquisition of RMM on 28 September 2016 based on the difference between the share capital issued by the Company and the share capital issued by RMM amounting to approximately RM59.49 million.